Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation

The need for agents to lower body copper in Wilson's disease, a disease which results from copper toxicity has been the driving force for the development of the effective anticopper drugs penicillamine, trientine, zinc, and now tetrathiomolybdate (TM). Because of its rapid action, potency, and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular and molecular medicine 2003-01, Vol.7 (1), p.11-20
Main Author: Brewer, G. J.
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Antiangiogenesis/Review Series
Angiogenesis Inhibitors - therapeutic use
Animal models
Animals
Chelation Therapy
Copper
Copper - metabolism
Cytokines - metabolism
Drug development
Fibrosis
Fibrosis - metabolism
Hepatolenticular Degeneration - drug therapy
Humans
Inflammation
Inflammation - metabolism
Molybdenum - therapeutic use
tetrathiomolybdate
Toxicity
Wilson's disease
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The need for agents to lower body copper in Wilson's disease, a disease which results from copper toxicity has been the driving force for the development of the effective anticopper drugs penicillamine, trientine, zinc, and now tetrathiomolybdate (TM). Because of its rapid action, potency, and safety, TM is proving to be a very effective drug for initial treatment of acutely ill Wilson's disease patients. Beyond this, TM has antiangiogenic effects, because many proangiogenic cytokines require normal levels of copper. This has led to use of TM in cancer, where it is generally effective in animal tumor models, and has shown efficacy in preliminary clinical studies. Most recently, it has been found that TM has antifibrotic and antiinflammatory effects through inhibition of profibrotic and proinflammatory cytokines.
ISSN:1582-1838
1582-4934
DOI:10.1111/j.1582-4934.2003.tb00198.x